Health Care·Pharmaceuticals·$276.4B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $1.06 | N/A | +0.06% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $1.06 | N/A | +0.06% |
| Revenue | N/A | N/A | N/A |
Tone: Cautiously Optimistic
Management expressed satisfaction with the EPS results but did not provide specific revenue figures. They emphasized their commitment to innovation and long-term growth.
We are pleased with our EPS performance this quarter.
Our focus remains on delivering value through our pipeline.
Merck's earnings report shows a slight EPS beat, which indicates some positive momentum in profitability. However, the stock reacted negatively, declining by 0.81%. The lack of revenue data and guidance may have contributed to investor uncertainty.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
TEXAS INSTRS INC
Jul 24, 2018